查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1809921

經頸靜脈肝內門體分流術 (TIPS) 市場（按產品類型、手術類型、最終用戶和應用）- 全球預測，2025-2030 年

Transjugular Intrahepatic Portosystemic Shunt Market by Product Type, Procedure Type, End User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年經頸靜脈肝內門體分流術 (TIPS) 市值為 1.026 億美元，預計 2025 年將成長至 1.0683 億美元，複合年成長率為 4.27%，到 2030 年將達到 1.3188 億美元。

主要市場統計數據
基準年2024年 1.026億美元
預計2025年 1.0683億美元
預測年份 2030 1.3188億美元
複合年成長率（%） 4.27%

無與倫比的臨床和技術創新為經頸靜脈肝內門體分流術 (TIPS) 治療的未來鋪平了道路

經頸靜脈肝內門體分流術 (TIPS) 是一項突破性的介入手術，旨在透過在肝臟內建立連接門靜脈和體靜脈循環的通道來緩解門靜脈高壓。這種微創方法自誕生以來取得了顯著進展，已從一項實驗通訊協定發展成為治療頑固性腹水、靜脈曲張出血、布加症候群和肝腎症候群等併發症的標準治療方法。多年來，支架設計、影像引導和技術的不斷改進，提高了 TIPSS 的安全性和臨床有效性，推動了其在心血管和肝病領域的應用。

引領創新進步，精準有效塑造經頸靜脈肝內門體分流術 (TIPS) 設置

由於器械工程和操作指導方面的突破性進展，經頸靜脈肝內門體分流術 (TIPS) 治療領域正在發生重大變革時期。現代覆膜支架技術顯著減少了支架內血管再阻塞和分流功能障礙，從而提高了門靜脈高壓症患者的通暢率並改善了患者的長期預後。同時，在成本和操作靈活性至關重要的情況下，裸金屬支架的改進仍發揮補充作用。

全面評估美國新關稅對經頸靜脈肝內門體分流術 (TIPS) 設備的可用性和可負擔性的影響。

2025年，美國對進口醫療設備徵收的新關稅生效，凸顯了TIPSS組件的經濟效益。進口支架及套件的附加稅導致專用移植物、球囊導管和擴張器的土地價格逐步上漲，給醫院採購預算帶來了上行壓力。隨著供應商重新評估其定價結構，醫療保健提供者正在評估替代籌資策略的成本效益。

揭示關鍵的細分觀點，揭示經頸靜脈肝內門體分流術 (TIPS) 市場分析和採用動態中的不同途徑

仔細研究產品類型細分，我們發現，儘管長期以來臨床上支架比附件更受青睞，但由於其在緩解分流功能障礙方面的卓越性能，人們已明顯轉向覆膜支架。在覆膜支架類別中，製造商正透過專有的覆膜塗層和混合金屬合金來平衡柔韌性和徑向強度，從而實現差異化。同時，球囊擴張器和導引鞘套等配件也在不斷發展，融入了低摩擦聚合物和增強的外形設計，以簡化器械輸送。

了解影響美洲、歐洲、中東、非洲和亞太地區經頸靜脈肝內門體分流術 (TIPS) 普及的區域動態和採用促進因素。

經頸靜脈肝內門體分流術 (TIPS) 療法的採用和發展在很大程度上受到區域因素的影響。在北美和南美，強大的報銷框架和高昂的醫療支出創造了有利於新支架技術快速整合的環境。大都會圈的卓越中心正在帶頭進行臨床試驗，而區域和社區醫院正在採用可擴展的程序平台來擴大患者獲得治療的機會。歐洲、中東和非洲各地不同的監管途徑和報銷計劃需要設備製造商和區域經銷商之間建立戰略合作夥伴關係。雖然西歐通常作為實踐模式的基準，但中東和非洲的新興市場對介入放射學投資表現出越來越濃厚的興趣。許多政府正在推出培訓計劃和官民合作關係，以建立當地專業知識和基礎設施。

2025 年經頸靜脈肝內門體分流術 (TIPS) 市場參與企業的策略創新、合作夥伴關係和競爭策略亮點

經子宮頸肝內濾過性肝動脈分流術市場的主要相關人員正在採取各種策略舉措，以增強其競爭地位。現有的醫療設備製造商正在大力投資研究合作和臨床合作，以改善植入生物材料和輸送系統。此類合作不僅加速了實驗室研究成果向商業性產品的轉化，也加強了與指導手術標準化的關鍵意見領袖的關係。

實施可行的策略指令，以提高經頸靜脈肝內門體分流術 (TIPS) 解決方案的臨床效果和市場滲透率

為了抓住新興機會並應對TIPSS領域的營運挑戰，產業領導者應優先對臨床醫生教育和手術模擬計畫進行有針對性的投資。透過培養對先進支架置入技術和影像整合的熟練，醫療中心可以降低併發症發生率並改善患者預後。此外，與肝病學會和放射學會建立合作夥伴關係，可就最佳實踐達成共識，並促進其在不同醫療機構的廣泛應用。

採用嚴格的混合調查方法，對經頸靜脈肝內門體分流術 (TIPS) 市場動態進行可靠且公正的洞察

本分析採用了嚴格的混合方法框架，其特點是整合了原始研究和二手資料。原始資料是透過與來自多個地區的介入放射科醫生、肝病科醫生、採購人員和監管事務專家進行深入訪談收集的。這些見解也透過查閱二手資料（包括同行評審日誌、設備註冊資訊、臨床試驗資料庫和公開的監管文件）進行了補充。

綜合關鍵發現以確定經頸靜脈肝內門體分流術 (TIPS) 技術和臨床應用的未來發展軌跡

臨床創新、不斷變化的監管格局以及供應鏈的調整交織在一起，共同構成了經頸靜脈肝內門體分流術 (TIPS) 的動態格局。塗層支架材料、影像處理化輸送系統以及遠端患者監護方面的突破性進展，共同改善了治療效果，重塑了治療模式。同時，不斷變化的關稅結構和區域報銷細則迫使相關人員最佳化製造地並完善打入市場策略。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 全球非酒精性脂肪性肝炎的盛行率不斷上升，推動了對 TIPS 手術的需求
  • ePTFE覆膜支架技術創新提升TIPS的長期通暢率
  • 整合影像引導導航系統以提高 TIPS 置放的準確性
  • 引進遠端醫療平台，用於遠距監測TIPS患者的術後狀況
  • 新型可生物分解支架獲監理機關核准，為TIPS市場帶來更多機會
  • 新興市場醫療保健投資的增加推動了TIPS干預措施的採用
  • 支援聯合TIPS和門靜脈栓塞術的混合手術室平台
  • 成本效益分析對醫院採用 TIPS 技術的影響日益重要
  • 制定標準化培訓計劃，提高臨床醫生對 TIPS 技術的熟練程度
  • 加強抗生素預防通訊協定可降低經頸靜脈分流手術後的感染率

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 經頸靜脈肝內門體分流術（TIPS）市場（依產品類型）

  • 配件
  • 支架
    • 裸金屬支架
    • 覆膜支架

9. 經頸靜脈肝內門體分流術（TIPS）市場（依手術類型）

  • 選擇性
  • 緊急狀況

10. 經頸靜脈肝內門體分流術（TIPS）市場（依最終使用者）

  • 門診中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 肝病中心
    • 放射中心

11. 經頸靜脈肝內門體分流術（TIPS）市場的應用

  • 布德-加利氏症候群
  • 肝腎症候群
    • 1型（HRS-1）
    • 2 型（HRS-2）
  • 頑固性腹水
    • 利尿不適當性腹水
    • 利尿劑抗性腹水
  • 靜脈曲張出血

12.美國經頸靜脈肝內門體分流術（TIPS）市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲經頸靜脈肝內門體分流術（TIPS）市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太經頸靜脈肝內門體分流術（TIPS）市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Boston Scientific Corporation
    • WL Gore & Associates, Inc.
    • Cook Group Incorporated
    • Becton, Dickinson and Company
    • AngioDynamics Inc.
    • Argon Medical Devices, Inc.
    • Siemens Healthineers AG
    • Merit Medical Systems, Inc.
    • Sirtex Medical Inc.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-562E923A956A

The Transjugular Intrahepatic Portosystemic Shunt Market was valued at USD 102.60 million in 2024 and is projected to grow to USD 106.83 million in 2025, with a CAGR of 4.27%, reaching USD 131.88 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 102.60 million
Estimated Year [2025] USD 106.83 million
Forecast Year [2030] USD 131.88 million
CAGR (%) 4.27%

Pioneering the Future of Transjugular Intrahepatic Portosystemic Shunt Therapy with Unmatched Clinical and Technological Innovations

Transjugular Intrahepatic Portosystemic Shunt (TIPSS) represents a landmark interventional procedure designed to alleviate portal hypertension by creating a channel that connects the portal and systemic venous circulations within the liver. This minimally invasive approach has evolved significantly since its inception, transitioning from experimental protocols to a standard of care for managing complications such as refractory ascites, variceal bleeding, Budd-Chiari syndrome, and hepatorenal syndrome. Over the years, continuous improvements in stent design, imaging guidance, and procedural techniques have enhanced both the safety profile and clinical efficacy of TIPSS, driving its adoption across cardiovascular and hepatology specialties.

Beyond clinical performance, TIPSS has catalyzed a broader transformation in interventional radiology workflows, prompting deeper collaboration between hepatologists and radiologists. With the expansion of imaging modalities such as intravascular ultrasound and cone-beam computed tomography, physicians can now achieve unparalleled precision during stent deployment. As practitioners refine patient selection criteria in line with evolving guidelines, those involved in device development, hospital procurement, and health policy recognize that sustaining these advances will require concerted efforts in training, evidence generation, and supply chain resilience.

Navigating Transformative Advances Reshaping the Transjugular Intrahepatic Portosystemic Shunt Landscape with Precision and Efficacy

The landscape of Transjugular Intrahepatic Portosystemic Shunt therapy has entered a phase of profound transformation driven by breakthroughs in device engineering and procedural guidance. Modern covered stent technologies have substantially reduced instances of in-stent restenosis and shunt dysfunction, thereby prolonging patency and improving long-term outcomes for patients with portal hypertension. Meanwhile, refinements to bare metal stents continue to play a complementary role where cost considerations and procedural flexibility are paramount.

Moreover, the integration of real-time imaging techniques has revolutionized interventional workflows. Advanced needle guidance systems and three-dimensional reconstruction software enable clinicians to navigate complex hepatic vasculature with unprecedented accuracy. As a result, complication rates have declined and procedural durations have shortened, paving the way for broader adoption in both tertiary care centers and specialized outpatient settings.

Furthermore, clinical guidelines have adapted to reflect these technological gains, expanding the indications for TIPSS to include patients with refractory ascites and select cases of hepatorenal syndrome. In parallel, remote monitoring solutions and digital health platforms are emerging to support post-procedural surveillance, ensuring early detection of shunt dysfunction and enhancing long-term patient management.

Evaluating the Comprehensive Impact of Emerging United States Tariff Measures on Transjugular Intrahepatic Portosystemic Shunt Device Accessibility and Affordability

In 2025, newly implemented U.S. tariff measures targeting imported medical devices have brought the economics of TIPSS components into sharp focus. Levies imposed on stent imports and accessory kits have incrementally increased the landed cost of specialized grafts, balloon catheters, and dilators, thereby exerting upward pressure on hospital procurement budgets. As suppliers reassess their price structures, healthcare providers are evaluating the cost-effectiveness of alternative sourcing strategies.

Consequently, device manufacturers are accelerating efforts to localize production within domestic facilities. By establishing U.S.-based manufacturing lines for covered stent materials and accessory assemblies, leading vendors are striving to mitigate tariff exposure and stabilize pricing. This shift also aligns with broader industry initiatives supporting supply chain resilience and operational continuity.

At the same time, hospital systems are leveraging group purchasing organizations and value-based contracting models to absorb incremental cost increases without compromising patient access. In some cases, providers have renegotiated service agreements to bundle TIPSS procedural costs with downstream imaging follow-up, thereby preserving overall reimbursement margins. Looking ahead, tighter collaboration between policy makers and industry stakeholders may be necessary to ensure that tariff policies support both innovation incentives and patient affordability.

Unveiling Critical Segmentation Perspectives That Illuminate Diverse Pathways in Transjugular Intrahepatic Portosystemic Shunt Market Analysis and Adoption Dynamics

An in-depth examination of product type segmentation reveals that stents have long dominated clinical preference over accessories, with a pronounced shift toward covered designs due to their superior performance in reducing shunt dysfunction. Within the covered stent category, manufacturers are differentiating through proprietary graft coatings and hybrid metal alloys aimed at balancing flexibility with radial strength. Meanwhile, accessories such as balloon dilators and guide sheaths continue to evolve, incorporating low-friction polymers and enhanced profile designs to streamline device delivery.

Turning to procedural segmentation, elective TIPSS placements account for a significant proportion of cases, driven by scheduled interventions for refractory ascites and variceal bleeding prevention. In contrast, emergency procedures are reserved for acute hemorrhagic events, where rapid access to specialized equipment and multidisciplinary coordination becomes critical. As a result, service providers are optimizing inventory allocation and on-call staffing to ensure readiness across both elective and emergent care pathways.

Insights into end-user dynamics show that hospitals remain the cornerstone of TIPSS delivery, with private institutions often pioneering new techniques and public hospitals extending access to underserved populations. Ambulatory centers are steadily expanding their role in lower-risk procedures, benefiting from streamlined reimbursement and shorter patient stays. Specialty clinics, particularly hepatology centers and radiology centers, are also carving out niche capabilities by offering integrated pre- and post-procedural care protocols that improve long-term patient monitoring and reduce readmission rates.

Application segmentation underscores the diverse clinical scenarios in which TIPSS provides therapeutic benefit. Management of Budd-Chiari syndrome and variceal bleeding continues to be a core indication, while refractory ascites cases-whether diuretic ineligible or diuretic resistant-are driving incremental adoption. Furthermore, the nuanced treatment of hepatorenal syndrome, spanning Type 1 and Type 2 presentations, is gaining traction as evidence mounts supporting early intervention. These varied applications collectively shape a dynamic market landscape in which device developers and care providers must tailor solutions to meet evolving clinical needs.

Deciphering Regional Dynamics and Adoption Drivers Influencing Transjugular Intrahepatic Portosystemic Shunt Utilization Across Americas EMEA and Asia-Pacific

Regional considerations profoundly influence the uptake and evolution of Transjugular Intrahepatic Portosystemic Shunt therapy. In North and South America, robust reimbursement frameworks and high healthcare expenditure create an environment conducive to the rapid integration of novel stent technologies. Centers of excellence in metropolitan areas spearhead clinical trials, while rural and community hospitals adopt scalable procedural platforms to broaden patient access. Across Europe, Middle East & Africa, variations in regulatory pathways and reimbursement schemes necessitate strategic alliances between device makers and regional distributors. Western Europe often serves as a bellwether for practice patterns, while emerging markets in the Middle East and Africa demonstrate growing interest in interventional radiology investments. Many governments are launching training initiatives and public-private partnerships to build local expertise and infrastructure.

Alternatively, the Asia-Pacific landscape features a dual trend of mature markets such as Japan and Australia embracing incremental innovations, and rapidly developing nations in Southeast Asia investing in capacity building. Rising incidences of liver disease, coupled with expanding healthcare coverage, are prompting hospitals and specialty clinics to incorporate TIPSS into their therapeutic portfolios. Moreover, regional consortiums are driving guidelines alignment, fostering consistency in patient selection and procedural protocols across borders.

Taken together, these diverse regional dynamics underscore the importance of a tailored approach to market entry, where local regulatory nuance, reimbursement environments, and clinical training frameworks converge to shape long-term adoption trajectories.

Highlighting Strategic Innovations, Collaborations, and Competitive Maneuvers by Leading Transjugular Intrahepatic Portosystemic Shunt Market Participants in 2025

Leading stakeholders in the Transjugular Intrahepatic Portosystemic Shunt market are deploying a range of strategic initiatives to consolidate their competitive positions. Established medical device conglomerates have invested heavily in research partnerships and clinical collaborations to refine graft biomaterials and delivery systems. These alliances not only accelerate the translation of laboratory findings into commercial offerings but also strengthen relationships with key opinion leaders who guide procedural standardization.

At the same time, agile innovators and start-ups are challenging the status quo with modular stent architectures and disposable accessory platforms designed to reduce inventory overhead. Several emerging players have secured breakthrough device designations, leveraging faster regulatory pathways in multiple regions. Furthermore, co-development agreements between global device manufacturers and local producers are on the rise, enabling tailored solutions that address specific market requirements such as cost containment and clinician preferences.

In addition, strategic acquisitions and licensing deals are enabling key participants to expand their intellectual property portfolios and bolster end-to-end service capabilities. As a result, integrated service models that combine device provision with advanced imaging support and procedural training are becoming a differentiator in high-growth markets. Collectively, these corporate maneuvers are reshaping the competitive landscape, heightening the importance of agility, customer engagement, and continuous innovation.

Implementing Actionable Strategic Directives to Amplify Clinical Efficacy and Market Penetration for Transjugular Intrahepatic Portosystemic Shunt Solutions

To capitalize on emerging opportunities and address operational challenges in the TIPSS domain, industry leaders should prioritize targeted investments in clinician education and procedural simulation programs. By fostering proficiency in advanced stent deployment techniques and imaging integration, medical centers can reduce complication rates and improve patient outcomes. Additionally, forging collaborative partnerships with hepatology and radiology societies will drive consensus on best practices, facilitating broader adoption across diverse care settings.

Another critical recommendation involves strengthening supply chain resilience through localization of key manufacturing processes. Establishing regional production hubs for graft materials and accessories not only mitigates the impact of international tariff fluctuations but also shortens lead times and supports emergency procedural readiness. Parallel to manufacturing strategies, device suppliers should engage with payers and health authorities to demonstrate the value proposition of TIPSS in reducing hospital admissions and long-term care costs.

Finally, organizations should develop data-driven post-market surveillance frameworks to capture real-world performance metrics. Leveraging digital health platforms and remote monitoring tools will enable continuous quality improvement, inform iterative device enhancements, and substantiate reimbursement claims. Collectively, these actionable steps will empower stakeholders to navigate regulatory complexities, reinforce clinical efficacy, and secure sustainable growth in a competitive marketplace.

Employing Rigorous Mixed Methodology Frameworks to Ensure Robust and Unbiased Insights into Transjugular Intrahepatic Portosystemic Shunt Market Dynamics

This analysis leverages a rigorous mixed methodology framework characterized by the integration of primary and secondary research. Primary inputs were gathered through in-depth interviews with interventional radiologists, hepatology specialists, procurement directors, and regulatory affairs experts across multiple regions. These insights were complemented by secondary source reviews, including peer-reviewed journals, device registries, clinical trial databases, and publicly available regulatory filings.

The approach further incorporated data triangulation techniques to validate findings and reconcile disparate viewpoints. Quantitative data points on procedural volumes, device utilization trends, and reimbursement policies were cross-referenced against qualitative perspectives from key opinion leaders. Additionally, the research team conducted a comprehensive competitor landscape assessment, combining patent analytics with corporate financial disclosures to uncover strategic trajectories.

Throughout the study, adherence to stringent quality protocols ensured the elimination of bias and the maintenance of analytical integrity. Continuous peer reviews and stakeholder consultations reinforced the credibility of the conclusions, delivering a robust foundation for strategic decision-making in the Transjugular Intrahepatic Portosystemic Shunt arena.

Synthesizing Key Findings to Illuminate the Future Trajectory of Transjugular Intrahepatic Portosystemic Shunt Technologies and Clinical Applications

The intersection of clinical innovation, regulatory evolution, and supply chain adaptation underscores the dynamic nature of the Transjugular Intrahepatic Portosystemic Shunt landscape. Breakthroughs in covered stent materials, imaging-enabled delivery systems, and remote patient monitoring are collectively enhancing procedural efficacy and reshaping treatment paradigms. Simultaneously, shifting tariff structures and regional reimbursement nuances are driving stakeholders to optimize manufacturing footprints and refine market access strategies.

Looking ahead, the continued expansion of TIPSS indications, including nuanced treatment of hepatorenal syndrome and refractory ascites subtypes, points toward sustained clinical demand. The competitive environment will likely intensify as established players deepen their offerings and emerging innovators introduce next-generation platforms. Against this backdrop, a data-driven approach to real-world evidence, collaborative guideline development, and adaptive reimbursement frameworks will be essential to unlock enduring value for both patients and healthcare systems.

In summary, the trajectory of TIPSS market evolution promises to be defined by the integration of advanced technologies, strategic partnerships, and an unwavering focus on patient outcomes. Stakeholders equipped with comprehensive insights and actionable recommendations will be best positioned to navigate this complex and rapidly evolving domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising global prevalence of nonalcoholic steatohepatitis driving demand for TIPS procedures
  • 5.2. Innovation in ePTFE covered stent technology improving long-term TIPS patency rates
  • 5.3. Integration of image-guided navigation systems enhancing precision in TIPS placement
  • 5.4. Adoption of telehealth platforms for postoperative monitoring of TIPS patients in remote regions
  • 5.5. Regulatory approvals for novel biodegradable stents expanding TIPS market opportunities
  • 5.6. Rising healthcare investments in emerging markets fueling uptake of TIPS interventions
  • 5.7. Hybrid operating room platforms supporting combined TIPS and portal vein embolization procedures
  • 5.8. Growing emphasis on cost-effectiveness analyses influencing hospital adoption of TIPS technology
  • 5.9. Development of standardized training programs improving clinician proficiency in TIPS techniques
  • 5.10. Enhanced antibiotic prophylaxis protocols reducing infection rates after transjugular shunt placement

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Transjugular Intrahepatic Portosystemic Shunt Market, by Product Type

  • 8.1. Introduction
  • 8.2. Accessories
  • 8.3. Stents
    • 8.3.1. Bare Metal Stent
    • 8.3.2. Covered Stent

9. Transjugular Intrahepatic Portosystemic Shunt Market, by Procedure Type

  • 9.1. Introduction
  • 9.2. Elective
  • 9.3. Emergency

10. Transjugular Intrahepatic Portosystemic Shunt Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Centers
  • 10.3. Hospitals
    • 10.3.1. Private Hospital
    • 10.3.2. Public Hospital
  • 10.4. Specialty Clinics
    • 10.4.1. Hepatology Center
    • 10.4.2. Radiology Center

11. Transjugular Intrahepatic Portosystemic Shunt Market, by Application

  • 11.1. Introduction
  • 11.2. Budd-Chiari Syndrome
  • 11.3. Hepatorenal Syndrome
    • 11.3.1. Type 1 Hrs
    • 11.3.2. Type 2 Hrs
  • 11.4. Refractory Ascites
    • 11.4.1. Diuretic Ineligible Ascites
    • 11.4.2. Diuretic Resistant Ascites
  • 11.5. Variceal Bleeding

12. Americas Transjugular Intrahepatic Portosystemic Shunt Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Transjugular Intrahepatic Portosystemic Shunt Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Transjugular Intrahepatic Portosystemic Shunt Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Boston Scientific Corporation
    • 15.3.2. W. L. Gore & Associates, Inc.
    • 15.3.3. Cook Group Incorporated
    • 15.3.4. Becton, Dickinson and Company
    • 15.3.5. AngioDynamics Inc.
    • 15.3.6. Argon Medical Devices, Inc.
    • 15.3.7. Siemens Healthineers AG
    • 15.3.8. Merit Medical Systems, Inc.
    • 15.3.9. Sirtex Medical Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHAI
  • FIGURE 24. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHSTATISTICS
  • FIGURE 25. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHCONTACTS
  • FIGURE 26. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COVERED STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COVERED STENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ELECTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ELECTIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY EMERGENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY EMERGENCY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY RADIOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY RADIOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BUDD-CHIARI SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BUDD-CHIARI SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 1 HRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 1 HRS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 2 HRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 2 HRS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC INELIGIBLE ASCITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC INELIGIBLE ASCITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC RESISTANT ASCITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC RESISTANT ASCITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY VARICEAL BLEEDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY VARICEAL BLEEDING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 145. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 149. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 163. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 166. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 178. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 179. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 180. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 228. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 229. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 231. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 233. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 234. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 235. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 236. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 245. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 246. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 247. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 248. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 249. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 251. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 252. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 253. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 254. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 259. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 264. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 265. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 267. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION,